# US 2026/0158146 A1 · External preparation comprising non-lamellar liquid crystal-forming lipid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0158146 A1
- Document ID: US20260158146A1
- Status: Published application
- Kind: A1
- Application number: 19/181,737
- Filed: 2025-04-17
- Published: 2026-06-11
- Earliest claimed: 2018-09-07
- Assignees: Farnex Incorporated
- Applicants: Farnex Incorporated
- Inventors: Kenji SUGIBAYASHI; Hiroaki TODO; Ichiro HIJIKURO; Masahisa TANOMURA; Sayaka MORI
- Web page: https://patentgrep.com/patent/US20260158146A1

## CPC

- A61K 9/1274: Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 8/0208: {Tissues; Wipes; Patches}
- A61K 8/0295: {Liquid crystals}
- A61K 8/046: {Aerosols; Foams}
- A61K 8/375: {the alcohol moiety containing more than one hydroxy group}
- A61K 8/60: Sugars; Derivatives thereof
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/7015: {Drug-containing film-forming compositions, e.g. spray-on}
- A61K 9/7061: {Polyacrylates}
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 17/00: Drugs for dermatological disorders
- A61Q 19/00: Preparations for care of the skin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates to an external preparation that is well retained on a living body surface and is capable of increasing drug permeability, in particular, an external preparation comprising a non-lamellar liquid crystal-forming lipid and a drug.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A liquid composition, comprising:
a non-lamellar crystal-forming lipid;
a drug; and
an aqueous medium.

### Claim 21 (depends on 20)

The liquid composition according to claim 20, which further comprises a solvent.

### Claim 22 (depends on 21)

The liquid composition according to claim 21, wherein the solvent is ethanol.

### Claim 23 (depends on 20)

The liquid composition according to claim 20, comprising a homogeneous mixture of the non-liquid crystal forming lipid, the drug, and the aqueous medium.

### Claim 24 (depends on 20)

The liquid composition according to claim 20, wherein the non-lamellar liquid crystal-forming lipid is an amphipathic compound represented by a general formula (I), or a salt thereof:
wherein X and Y each denotes a hydrogen atom, or X and Y together denote an oxygen atom;
wherein n denotes an integer from 0 to 2;
wherein m denotes an integer that is 1 or 2;
wherein denotes a single bond or a double bond; and
wherein R denotes a hydrophilic group having two or more hydroxyl groups.

### Claim 25 (depends on 24)

The liquid composition according to claim 24, wherein R denotes a hydrophilic group substituent generated by removal of one hydroxyl group from a compound selected from the group consisting of glycerol, erythritol, pentaerythritol, diglycerol, glyceric acid, triglycerol, xylose, sorbitol, ascorbic acid, glucose, galactose, mannose, dipentaerythritol, maltose, mannitol, and xylitol.

### Claim 26 (depends on 20)

The liquid composition according to claim 20, wherein the non-lamellar liquid crystal-forming lipid is mono-O-(5,9,13,17-tetramethyloctadec-4-enoyl)glycerol or mono-O-(5,9,13-trimethyltetradec-4-enoyl)glycerol.

### Claim 27 (depends on 20)

The liquid composition according to claim 20, wherein the non-lamellar liquid crystal-forming lipid is phytantriol.

### Claim 28 (depends on 20)

The liquid composition according to claim 20, which further comprises a surfactant.

### Claim 29 (depends on 20)

The liquid composition according to claim 20, wherein the drug is a water-soluble drug.

### Claim 30 (depends on 20)

An external preparation comprising the liquid composition according to claim 20.

### Claim 31 (depends on 30)

The external preparation according to claim 30, which is a spray formulation.

### Claim 32 (depends on 31)

The external preparation according to claim 31, wherein the spray formulation is an aerosol formulation further comprising a propellant.

### Claim 33 (depends on 30)

The external preparation according to claim 30, which is a patch.

### Claim 34 (depends on 33)

The external preparation according to claim 33, wherein the patch is a tape formulation having an adhesive layer comprising the liquid composition and an adhesive.

### Claim 35 (depends on 34)

The external preparation according to claim 34, wherein the external preparation comprises the adhesive at 70 w/w % or more, relative to a total weight of the adhesive layer.
